Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Down syndrome and Alzheimer's

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

During alteplase administration, the patient experienced clinical deterioration. A subsequent CT scan evidenced an intracranial hemorrhagic transformation (Figure 2). Thereafter, an MRI from 2018 was reviewed, demonstrating lobar microbleeds consistent with suspected CAA, although no prior diagnosis had been established (Figure 3). Despite significant hemorrhage, the patient demonstrated unexpected clinical improvement. CAA is particularly common in DSAD due to the genetic foundation of AD, which accelerates beta-amyloid pathology in both the brain parenchyma and blood vessels. This case underscores a significant gap in the literature concerning the coexistence of CAA in DSAD and acute ischemic stroke. Presently, there is no established evidence to guide management in such cases, and this issue is likely underreported due to limited data on reperfusion therapy for stroke in individuals with DS. The genetic characteristics of DSAD present a unique opportunity to explore the progression and interplay of these conditions, potentially providing valuable insights to inform treatment strategies and enhance outcomes for all patients.

What this study adds

Evidence grade: Low

This case report describes a person with Down syndrome and Alzheimer's disease who had a brain hemorrhage after stroke treatment, with evidence of cerebral amyloid angiopathy. It highlights that there is no established guidance for managing this combination, and more data are needed.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Maure‐Blesa, L., Pichot, M. B., Rodríguez‐Baz, Í., Fernández, P. C., Arranz, J., Arriola‐Infante, J. E., et al. (2025). Challenges in Managing Cerebral Amyloid Angiopathy in Alzheimer's Disease: Insights from a Case of Down Syndrome‐associated Alzheimer Disease (DSAD). Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_100856

Vancouver

Maure‐Blesa L, Pichot MB, Rodríguez‐Baz Í, Fernández PC, Arranz J, Arriola‐Infante JE, et al. Challenges in Managing Cerebral Amyloid Angiopathy in Alzheimer's Disease: Insights from a Case of Down Syndrome‐associated Alzheimer Disease (DSAD). Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_100856. PMID: 41447445.

BibTeX

@article{maureblesa2025-41447445,
  author  = {Maure‐Blesa, Lucía and Pichot, Maria Borrell and Rodríguez‐Baz, Íñigo and Fernández, Patricia Carbonell and Arranz, Javier and Arriola‐Infante, José Enrique and Aranha, Mateus Rozalem and Bejanin, Alexandre and others},
  title   = {{Challenges in Managing Cerebral Amyloid Angiopathy in Alzheimer's Disease: Insights from a Case of Down Syndrome‐associated Alzheimer Disease (DSAD)}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_100856},
  pmid    = {41447445},
  url     = {https://doi.org/10.1002/alz70856_100856}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This case report describes a person with Down syndrome and Alzheimer's disease who had a brain hemorrhage after stroke treatment, with evidence of cerebral amyloid angiopathy. It highlights that there is no established guidance for managing this combination, and more data are needed.

Study details

How this study scored 33/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 33 of 100.33 of 100 points earned67 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author María Carmona‐Iragui: h-index 42 (OpenAlex, whole career)
Institution's track record 1 / 3 Universitat Autònoma de Barcelona: institution h-index 782 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41447445)
Free to read 2 / 2 Free to read
Total 33 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Down syndrome and Alzheimer's from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →